eMedicine Specialties > Dermatology > Diseases of the Subcutaneous Tissue

Lipodystrophy, Localized

Robert A Schwartz, MD, MPH, Professor and Head of Dermatology, Professor of Medicine, Professor of Pediatrics, Professor of Pathology, Professor of Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School
Isabelle Thomas, MD, Associate Professor, Department of Dermatology, University of Medicine and Dentistry of New Jersey, New Jersey Medical School; Chief of Dermatology Service, Veterans Affairs Medical Center of East Orange

Updated: Apr 29, 2008

Introduction

Background

Lipodystrophies are a heterogeneous group of diseases clinically characterized by a congenital or acquired loss of fat in circumscribed, partial, or diffuse areas of the body. As a rule, localized lipodystrophies are not associated with metabolic or systemic disorders, they tend to resolve spontaneously, and they have an excellent prognosis. The main concern is cosmetic when the lesions persist. Controversy exists in their classification, but 3 subsets can be identified based on the presence or the absence of preceding inflammation and the histologic findings.

Centrifugal lipodystrophy or lipodystrophia centrifugalis abdominalis infantilis is the best-characterized subset. It affects children at a young age. It begins on the trunk, spreads for a few years to the neighboring abdomen or chest, and eventually resolves spontaneously in most patients.

The second group is defined by a lack of preceding inflammation and a common histologic pattern of involutional lipoatrophy. It includes such entities as lipoatrophia semicircularis; semicircular or annular dystrophy; and lipoatrophies linked to repeated trauma, pressure, or drug injections. A number of cases are idiopathic.

The third type represents a sequela from various types of panniculitis and is associated with preceding inflammation. It includes lipophagic granulomatous panniculitis and other types of panniculitis, primarily associated with connective-tissue disease.

Some other eMedicine articles on lipodystrophy include the following:

Lipodystrophy, Generalized
Lipodystrophy, HIV
Lipodystrophy, Progressive

A related Medscape CME course is A Randomized, Multicenter, Open-Label Study of Poly-L-Lactic Acid for HIV-1 Facial Lipoatrophy.

Pathophysiology

The pathophysiology of localized lipodystrophy is unknown. The pathogenetic mechanism of inherited lipodystrophies at the molecular level has been linked to mutations of lamin A/C, peroxisome proliferator-activated receptor (PPAR-gamma), and other seemingly unrelated proteins.¹ In cases linked to injections of insulin, an immune response mediated by tumor necrosis factor-alpha has been hypothesized.

Familial partial lipodystrophy (FPLD) usually results from coding sequence mutations either in LMNA, encoding nuclear lamin A/C, or in peroxisome proliferator-activated receptor-gamma (PPARG), encoding PPAR-gamma. The LMNA form is called FPLD2 (Mendelian Inheritance in Man [MIM] 151660) and the PPARG form is called FPLD3 (MIM 604367). FPLD phenotype may be due to a single-base mutation in the DNA-binding domain of peroxisome PPAR-gamma.² Impaired PPARG function through a mutation of a conserved salt bridge (R425C) producing FPLD has also been described.³

Frequency

International

Few cases have been reported internationally. Centrifugal lipodystrophy and the involutional type are rare. Lipoatrophy secondary to panniculitis is more frequent.

Mortality/Morbidity

Localized lipodystrophies usually have little or no associated morbidity or mortality. They are circumscribed and tend to resolve spontaneously, although panniculitis may be chronic and relapsing. Usually, no associated systemic disorder is present, except in some cases of panniculitis induced by an underlying connective-tissue disorder. Even then, symptoms tend to be mild with an excellent overall outcome.

Race

No racial predilection exists except for centrifugal lipodystrophy, which has been described mainly in Asian children.

Sex

No difference in sex has been established, except for a female predominance in the involutional type. A female predominance is also observed in connective-tissue disorder–associated lipoatrophic panniculitis.

Age

No specific age of onset exists except for centrifugal lipodystrophy. In these cases, lesions appear before age 3 years, they stop spreading by age 8 years, and they tend to resolve by age 13 years.

Connective-tissue disorder–associated lipoatrophic panniculitis may be observed at any age, but it occurs most frequently in adults aged 20-60 years. Lupus erythematosus is the most common underlying disease.

Clinical

History

Lipodystrophia centrifugalis is defined by the appearance of cutaneous lesions surrounded by a peripheral erythematous border before age 3 years. They may progress centrifugally for as long as 10 years and tend to regress thereafter. Children who are affected are healthy.
Involutional lipoatrophy is characterized by one or a few circumscribed depressions of the skin affecting any part of the body in persons of any age, with or without a history of previous trauma, pressure, or previous injections in the area.⁴ Clinically, it usually appears as a solitary, asymptomatic, well-demarcated, atrophic depression and often involves areas of antecedent intramuscular or intra-articular injections.^5,6,7 Overlying hypopigmentation and atrophy with morphealike changes may be noted with histology studies.
Panniculitis precedes the onset of lipoatrophy in the inflammatory subsets but may be asymptomatic clinically.

Physical

Lipodystrophia centrifugalis abdominalis infantilis, as originally described by Imamura et al⁸ in 1971, presents as a round or oval depression in the skin, often in the groin or the axilla. The overlying skin is of normal texture and color except for the periphery, which may be erythematous and a little scaly. Lesions tend to spread centrifugally to adjacent areas, such as the chest and the abdomen, for several years. The face and the sacral area can also be involved. Regional enlarged lymph nodes can often be palpated. No other abnormal finding is present clinically.
Involutional lipoatrophy is characterized by one or a few circumscribed depressions or indentations in the skin. The lesions are round, oval, bandlike, horizontal, annular, or semicircular in configuration. They are flesh colored and barely visible with normal overlying skin. The anterior parts of the thighs, the buttocks, or the lower parts of the limbs, including the ankles in some cases, as well as the arms, the neck, and the scalp may be involved, unilaterally or bilaterally. The lesions may be mildly tender at first. No associated finding and no preceding sign of inflammation are present.
Localized lipoatrophy may represent the late stage of panniculitis. Indurated, tender, erythematous, purplish or hyperpigmented subcutaneous nodules or plaques usually involving the extremities precede the onset of lipoatrophy at the same sites.
Fever and systemic signs may be present depending on the type of associated panniculitis.
- Lipophagic panniculitis of childhood, first described by Winkelmann et al in children and later in adults, is characterized by its benign self-limited course. It presents with multiple, slightly tender, erythematous subcutaneous nodules and plaques, which precede the onset of lipoatrophy. The lesions mainly occur on the extremities. It may recur several times, and it may be associated with intermittent fever.
- Localized lipoatrophy may be the only presenting feature in patients with an underlying or evolving connective-tissue disorder, such as lupus erythematosus, morphea profunda, dermatomyositis,⁹ or overlap disease. In patients with lupus panniculitis, multiple, often painful subcutaneous nodules or plaques, with a predilection for the proximal extremities, may be observed in association with irregular, indurated depressions in the same areas. The overlying skin is often normal, or changes, such as atrophy, hyperkeratosis, telangiectasias, and/or ulceration, seen in discoid lupus erythematosus may be present. Arthralgias or Raynaud syndrome may be observed, but most patients show no evidence of severe systemic involvement, such as glomerulonephritis or neurologic complications.

Causes

The cause of centrifugal lipodystrophy is unknown.
In many cases, involutional lipodystrophy is idiopathic. In other cases, repeated trauma, chronic pressure or compression, or local injections may be the cause. It has been reported to develop at the site of injection or in the surrounding area of injection with insulin, intralesional or intra-articular steroids, antibiotics (eg, intramuscular benzathine penicillin), vasopressin, and human growth hormone.
Localized lipoatrophy may represent the late or end stage of a preceding or concomitant panniculitis, which may be triggered by various underlying conditions. Connective-tissue disease–induced panniculitis is one of the main causes and may not be symptomatic at the time of presentation. Other causes of lipoatrophic panniculitis may include alpha-1-antitrypsin deficiency or cytophagic, factitial, and infectious panniculitides.

Differential Diagnoses

Lawrence-Seip Syndrome
Lipodystrophy, HIV
Lipodystrophy, Progressive
Morphea

Workup

Laboratory Studies

No associated laboratory abnormalities are present in most cases of localized lipodystrophy.
Complete blood counts, chemistry, erythrocyte sedimentation rate, renal function tests, and serum antibody tests should be performed in search of an underlying autoimmune condition in cases associated with panniculitis.
- A transient microcytic anemia, thrombocytosis, and elevated erythrocyte sedimentation rate have been reported in cases of lipophagic panniculitis.
- Serum antinuclear antibodies may be positive in cases associated with an autoimmune disorder.

Procedures

A skin biopsy of an affected area deep enough to include the subcutaneous tissue should be performed to confirm the diagnosis and to exclude underlying conditions. Direct immunofluorescence testing should be requested.

Histologic Findings

Centrifugal lipodystrophy is characterized by a loss of fat in the depressed area and evidence of panniculitis in the surrounding inflammatory area.

A pattern of involutional lipoatrophy is the common finding in the second subgroup, whether idiopathic or associated with a history of trauma, pressure, or local injections. Individual adipocytes and fat lobules are smaller and fewer, separated by hyaline material, with prominent and numerous capillaries, and minimal or no inflammation is present. No foreign body giant cell or lipophage is present.

Histologic evidence of panniculitis is usually present if a biopsy is performed on lesions early enough in the third subgroup. A combination of lipoatrophy and a predominantly lymphocytic or histiocytic infiltrate made of lipophages is most commonly found. Other features may vary with the underlying cause of panniculitis.

Lipophagic panniculitis is characterized by a panlobular panniculitis with a predominantly histiocytic infiltrate made of foamy and Toutonlike lipophages in the subcutaneous and periappendageal fat, giving it a granulomatous appearance. Immunofluorescence study findings are negative.

In cases of panniculitis associated with connective-tissue disorders, histopathologic findings may be diagnostic of lupus, scleroderma, dermatomyositis, or overlap disease, but they are not always specific. Lupus panniculitis is best defined as a mostly lobular panniculitis with a predominantly lymphocytic infiltrate. Lymphoid follicles with germinal centers around the septa and hyaline fat necrosis, when present, are characteristic. Changes may be confined to the subcutaneous tissue in about one half of cases, or the overlying epidermis and dermis may show evidence of discoid lupus erythematosus, such as epidermal atrophy, hyperkeratosis, hydropic degeneration of the dermoepidermal junction, and perivascular and appendageal lymphocytic infiltration of the overlying skin. Direct immunofluorescence findings are positive in most patients, with linear deposits of immunoglobulin M and C3 along the dermoepidermal junction.

Morphea profunda shows thickening and hyalinization of the septal panniculus and fascia. Small aggregates of lymphocytes and plasma cells as well as eosinophils may be observed and help in differentiating it from lupus.

Treatment

Medical Care

No treatment is usually needed, and lesions tend to regress spontaneously in many cases.

Intralesional steroids may be helpful in some cases.
When associated with an autoimmune disorder, antimalarials or systemic corticosteroids may be needed.

Surgical Care

No surgical care is needed as a rule. If cosmetically a problem, a combination of liposuction and localized fat transplantation may be used.

Medication

No medications are effective other than those indicated for a primary inflammatory panniculitis when present.

Follow-up

Further Outpatient Care

Follow-up care may be useful to document spontaneous regression and/or to make decisions for further treatment.
Patients may need to be monitored in cases preceded by panniculitis, particularly in cases associated with a connective-tissue disorder.

Prognosis

The prognosis is excellent in the first 2 groups because they are limited disorders affecting only localized areas of subcutaneous tissue.
The prognosis for patients with an underlying systemic illness follows that of the primary condition.
Many patients show spontaneous regression.

Miscellaneous

Medicolegal Pitfalls

Failure to recognize preceding panniculitis and its underlying causes

References

Capanni C, Mattioli E, Columbaro M, Lucarelli E, Parnaik VK, Novelli G, et al. Altered pre-lamin A processing is a common mechanism leading to lipodystrophy. Hum Mol Genet. Jun 1 2005;14(11):1489-502. [Medline].
Monajemi H, Zhang L, Li G, Jeninga EH, Cao H, Maas M, et al. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma. J Clin Endocrinol Metab. May 2007;92(5):1606-12. [Medline].
Jeninga EH, van Beekum O, van Dijk AD, Hamers N, Hendriks-Stegeman BI, Bonvin AM, et al. Impaired Peroxisome Proliferator-Activated Receptor {gamma} Function through Mutation of a Conserved Salt Bridge (R425C) in Familial Partial Lipodystrophy. Mol Endocrinol. May 2007;21(5):1049-65. [Medline].
Dahl PR, Zalla MJ, Winkelmann RK. Localized involutional lipoatrophy: a clinicopathologic study of 16 patients. J Am Acad Dermatol. Oct 1996;35(4):523-8. [Medline].
Aviles-Izquierdo JA, Longo-Imedio MI, Hernanz-Hermosa JM, Lazaro-Ochaita P. Bilateral localized lipoatrophy secondary to a single intramuscular corticosteroid injection. Dermatol Online J. Mar 30 2006;12(3):17. [Medline].
Ball NJ, Cowan BJ, Moore GR, Hashimoto SA. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases. J Cutan Pathol. Apr 2008;35(4):407-10. [Medline].
Abbas O, Salman S, Kibbi AG, Chedraoui A, Ghosn S. Localized involutional lipoatrophy with epidermal and dermal changes. J Am Acad Dermatol. Mar 2008;58(3):490-3. [Medline].
Imamura S, Yamada M, Ikeda T. Lipodystrophia centrifugalis abdominalis infantilis. Arch Dermatol. Sep 1971;104(3):291-8. [Medline].
Commens C, O'Neill P, Walker G. Dermatomyositis associated with multifocal lipoatrophy. J Am Acad Dermatol. May 1990;22(5 Pt 2):966-9. [Medline].
Ahn S, Yoo M, Lee S, Choi E. A clinical and histopathological study of 22 patients with membranous lipodystrophy. Clin Exp Dermatol. Jul 1996;21(4):269-72. [Medline].
André P. [Post-cortisone lipo-atrophy treated by an autologous graft of adipose cell islets]. Ann Dermatol Venereol. 1990;117(10):733-4. [Medline].
Atlan-Gepner C, Bongrand P, Farnarier C, Xerri L, Choux R, Gauthier JF, et al. Insulin-induced lipoatrophy in type I diabetes. A possible tumor necrosis factor-alpha-mediated dedifferentiation of adipocytes. Diabetes Care. Nov 1996;19(11):1283-5. [Medline].
Capeau J, Magre J, Lascols O, Caron M, Bereziat V, Vigouroux C. [Primary lipodystrophies]. Ann Endocrinol (Paris). Feb 2007;68(1):10-20. [Medline].
Gruber PC, Fuller LC. Lipoatrophy semicircularis induced by trauma. Clin Exp Dermatol. May 2001;26(3):269-71. [Medline].
Hagari Y, Sasaoka R, Nishiura S, Ishihara M, Mihara M, Shimao S. Centrifugal lipodystrophy of the face mimicking progressive lipodystrophy. Br J Dermatol. Oct 1992;127(4):407-10. [Medline].
Handfield-Jones SE, Stephens CJ, Mayou BJ, Black MM. The clinical spectrum of lipoatrophic panniculitis encompasses connective tissue panniculitis. Br J Dermatol. Nov 1993;129(5):619-24. [Medline].
Imamura S, Yamada M, Yamamoto K. Lipodystrophia centrifugalis abdominalis infantilis. A follow-up study. J Am Acad Dermatol. Aug 1984;11(2 Pt 1):203-9. [Medline].
Karkavitsas C, Miller JA, Kirby JD. Semicircular lipoatrophy. Br J Dermatol. Nov 1981;105(5):591-3. [Medline].
Kayikcioglu A, Akyurek M, Erk Y. Semicircular lipoatrophy after intragluteal injection of benzathine penicillin. J Pediatr. Jul 1996;129(1):166-7. [Medline].
Martinez A, Malone M, Hoeger P, Palmer R, Harper JI. Lipoatrophic panniculitis and chromosome 10 abnormality. Br J Dermatol. May 2000;142(5):1034-9. [Medline].
Perrot H. [Localized lipo-atrophies]. Ann Dermatol Venereol. 1988;115(4):523-7. [Medline].
Peters MS, Su WP. Panniculitis. Dermatol Clin. Jan 1992;10(1):37-57. [Medline].
Peters MS, Winkelmann RK. Localized lipoatrophy (atrophic connective tissue disease panniculitis). Arch Dermatol. Dec 1980;116(12):1363-8. [Medline].
Peters MS, Winkelmann RK. The histopathology of localized lipoatrophy. Br J Dermatol. Jan 1986;114(1):27-36. [Medline].
Reeves WG, Allen BR, Tattersall RB. Insulin-induced lipoatrophy: evidence for an immune pathogenesis. Br Med J. Jun 21 1980;280(6230):1500-3. [Medline].
Requena L, Sánchez Yus E. Panniculitis. Part II. Mostly lobular panniculitis. J Am Acad Dermatol. Sep 2001;45(3):325-61; quiz 362-4. [Medline].
Rongioletti F, Rebora A. Annular and semicircular lipoatrophies. Report of three cases and review of the literature. J Am Acad Dermatol. Mar 1989;20(3):433-6. [Medline].
Roth DE, Schikler KN, Callen JP. Annular atrophic connective tissue panniculitis of the ankles. J Am Acad Dermatol. Nov 1989;21(5 Pt 2):1152-6. [Medline].
Shelley WB, Izumi AK. Annular atrophy of the ankles. A case of partial lipodystrophy. Arch Dermatol. Sep 1970;102(3):326-9. [Medline].
Tremeau-Martinage C, Bayle-Lebey P, Grouteau E, Bazex J. Localized lipoatrophia with persistent circulating autoantibodies and partial immunoglobulin A deficiency in a child. Dermatology. 1996;192(4):353-7. [Medline].
Tsuji T, Kosaka K, Terao J. Localized lipodystrophy with panniculitis: light and electron microscopic studies. J Cutan Pathol. Dec 1989;16(6):359-64. [Medline].
Umbert IJ, Winkelmann RK. Adult lipophagic atrophic panniculitis. Br J Dermatol. Mar 1991;124(3):291-5. [Medline].
van Gurp PJ, Tack CJ, van der Valk M, Reiss P, Lenders JW, Sweep FC, et al. Sympathetic nervous system function in HIV-associated adipose redistribution syndrome. AIDS. Mar 21 2006;20(5):773-5. [Medline].
Winkelmann RK, McEvoy MT, Peters MS. Lipophagic panniculitis of childhood. J Am Acad Dermatol. Nov 1989;21(5 Pt 1):971-8. [Medline].

Keywords

localized lipoatrophy, lipodystrophia centrifugalis abdominalis infantilis, centrifugal lipoatrophy, annular lipoatrophy, semicircular lipoatrophy, lipoatrophia semicircularis, involutional lipoatrophy, lipophagic granulomatous panniculitis, lipoatrophic panniculitis

Contributor Information and Disclosures

Author

Robert A Schwartz, MD, MPH, Professor and Head of Dermatology, Professor of Medicine, Professor of Pediatrics, Professor of Pathology, Professor of Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School
Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi
Disclosure: Nothing to disclose.

Coauthor(s)

Isabelle Thomas, MD, Associate Professor, Department of Dermatology, University of Medicine and Dentistry of New Jersey, New Jersey Medical School; Chief of Dermatology Service, Veterans Affairs Medical Center of East Orange
Isabelle Thomas, MD is a member of the following medical societies: American Academy of Dermatology and Sigma Xi
Disclosure: Nothing to disclose.

Medical Editor

Daniel Mark Siegel, MD, MS, Director, Procedural Dermatology Fellowship Program, Clinical Professor of Dermatology, Department of Dermatology, State University of New York Downstate
Daniel Mark Siegel, MD, MS is a member of the following medical societies: American Academy of Dermatology, American Academy of Facial Plastic and Reconstructive Surgery, American College of Mohs Micrographic Surgery and Cutaneous Oncology, American College of Physician Executives, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, American Society for MOHS Surgery, and International Society for Dermatologic Surgery
Disclosure: Nothing to disclose.

Pharmacy Editor

David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Director, Division of Dermatology, Scott and White Clinic; Director Dermatology Residency Training Program, Scott and White Clinic
David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa
Disclosure: 3M Pharmaceutical Grant/research funds Other; Graceway Pharmaceuticals Grant/research funds Other

Managing Editor

Jeffrey P Callen, MD, Professor of Medicine, Chief, Division of Dermatology, University of Louisville School of Medicine
Jeffrey P Callen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and American College of Rheumatology
Disclosure: Amgen Honoraria Consulting; Abbott Honoraria Consulting; Electrical Optical Sciences Honoraria Consulting; Centocor Honoraria Consulting

CME Editor

Glen H Crawford, MD, Assistant Clinical Professor, Department of Dermatology, University of Pennsylvania School of Medicine; Chief, Division of Dermatology, The Pennsylvania Hospital
Glen H Crawford, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Phi Beta Kappa, and Society of USAF Flight Surgeons
Disclosure: Nothing to disclose.

Chief Editor

William D James, MD, Paul R Gross Professor of Dermatology, University of Pennsylvania School of Medicine; Vice-Chair, Program Director, Department of Dermatology, University of Pennsylvania Health System
William D James, MD is a member of the following medical societies: American Academy of Dermatology and Society for Investigative Dermatology
Disclosure: elsevier Royalty Other; american college of physicians Honoraria Other

Further Reading